Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.
Bon G, Pizzuti L, Laquintana V, Loria R, Porru M, Marchiò C, Krasniqi E, Barba M, Maugeri-Saccà M, Gamucci T, Berardi R, Livi L, Ficorella C, Natoli C, Cortesi E, Generali D, La Verde N, Cassano A, Bria E, Moscetti L, Michelotti A, Adamo V, Zamagni C, Tonini G, Barchiesi G, Mazzotta M, Marinelli D, Tomao S, Marchetti P, Valerio MR, Mirabelli R, Russo A, Fabbri MA, D'Ostilio N, Veltri E, Corsi D, Garrone O, Paris I, Sarobba G, Giotta F, Garufi C, Cazzaniga M, Del Medico P, Roselli M, Sanguineti G, Sperduti I, Sapino A, De Maria R, Leonetti C, Di Leo A, Ciliberto G, Falcioni R, Vici P. Bon G, et al. Among authors: falcioni r. J Exp Clin Cancer Res. 2020 Dec 10;39(1):279. doi: 10.1186/s13046-020-01797-3. J Exp Clin Cancer Res. 2020. PMID: 33302999 Free PMC article.
Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers.
Bon G, Loria R, Amoreo CA, Verdina A, Sperduti I, Mastrofrancesco A, Soddu S, Diodoro MG, Mottolese M, Todaro M, Stassi G, Milella M, De Maria R, Falcioni R. Bon G, et al. Among authors: falcioni r. Oncotarget. 2016 Aug 19;8(65):108463-108479. doi: 10.18632/oncotarget.11400. eCollection 2017 Dec 12. Oncotarget. 2016. PMID: 29312543 Free PMC article.
SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma.
Loria R, Laquintana V, Scalera S, Fraioli R, Caprara V, Falcone I, Bazzichetto C, Di Martile M, Rosanò L, Del Bufalo D, Bossi G, Sperduti I, Terrenato I, Visca P, Soddu S, Milella M, Ciliberto G, Falcioni R, Ferraresi V, Bon G. Loria R, et al. Among authors: falcioni r. J Exp Clin Cancer Res. 2022 Apr 19;41(1):148. doi: 10.1186/s13046-022-02354-w. J Exp Clin Cancer Res. 2022. PMID: 35440004 Free PMC article.
HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance.
Loria R, Laquintana V, Bon G, Trisciuoglio D, Frapolli R, Covello R, Amoreo CA, Ferraresi V, Zoccali C, Novello M, Del Bufalo D, Milella M, Biagini R, D'Incalci M, Falcioni R. Loria R, et al. Among authors: falcioni r. Oncogene. 2018 Nov;37(45):5926-5938. doi: 10.1038/s41388-018-0394-x. Epub 2018 Jul 6. Oncogene. 2018. PMID: 29980789 Free PMC article.
ATM kinase sustains HER2 tumorigenicity in breast cancer.
Stagni V, Manni I, Oropallo V, Mottolese M, Di Benedetto A, Piaggio G, Falcioni R, Giaccari D, Di Carlo S, Sperati F, Cencioni MT, Barilà D. Stagni V, et al. Among authors: falcioni r. Nat Commun. 2015 Apr 16;6:6886. doi: 10.1038/ncomms7886. Nat Commun. 2015. PMID: 25881002 Free article.
Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas.
Folgiero V, Avetrani P, Bon G, Di Carlo SE, Fabi A, Nisticò C, Vici P, Melucci E, Buglioni S, Perracchio L, Sperduti I, Rosanò L, Sacchi A, Mottolese M, Falcioni R. Folgiero V, et al. Among authors: falcioni r. PLoS One. 2008 Feb 13;3(2):e1592. doi: 10.1371/journal.pone.0001592. PLoS One. 2008. PMID: 18270579 Free PMC article.
83 results